Market Overview

UPDATE: Credit Suisse Upgrades Boston Scientific to Outperform on Improving Top-Line

Share:
Related BSX
Stocks Hitting 52-Week Highs
Earnings Scheduled For April 27, 2016
Big Cap Stocks Struggle, But A Few Charts Stand Out (Investor's Business Daily)

Credit Suisse upgraded Boston Scientific (NYSE: BSX) from Neutral to Outperform and raised the price target from $6.00 to $7.50.

Credit Suisse noted, ": We're upgrading BSX to Outperform from Neutral given increased visibility into meaningful top-line improvement. We forecast 4% WW CC growth for BSX in 2014 (4% CAGR 2013-17), a significant uptick relative to low-to-mid single digit declines 2010-13. We see the acceleration driven by key pipeline areas with Asthmatx, S-ICD, left atrial appendage closure, TAVI, renal denervation & DBS growing at a combined 57% CAGR 2013-17 to ~13% of BSX' 2017 sales (up from <1% currently)."

Boston Scientific closed at $6.32 on Monday.

Latest Ratings for BSX

DateFirmActionFromTo
Mar 2016NomuraInitiates Coverage onBuy
Feb 2016SunTrust Robinson HumphreyInitiates Coverage onBuy
Nov 2015CitigroupInitiates Coverage onBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (BSX)

View Comments and Join the Discussion!